COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking
NCT ID: NCT04408339
Last Updated: 2020-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2020-04-15
2022-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening of Cancer Patients to Assess Impact of COVID-19
NCT04373005
Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.
NCT04567979
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
NCT04298333
Immunological Responses of COVID-19 Vaccination
NCT05238467
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
NCT00382733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
(i) as a cancer patient during regular aftercare appointments who reports a current or past COVID-19 infection.
(ii) as an acute COVID-19 patient who reports a prevalent cancer diagnosis
Data will be collected as available from routine clinical care and includes demographic and biometric data, medical history, baseline data at inclusion as well as inpatient and intensive care unit admissions. Upon consent, patients will provide peripheral blood samples at time of inclusion and after 6 month. Recruitment is limited to a one-year period (April 2020 - April 2021).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention
No Intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Known diagnosis of CoVID-19 infection
* Age ≥ 18 years
* Signed informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hopsital Schleswig Holstein Campus Lübeck
OTHER
University Hospital Schleswig-Holstein
OTHER
Universitätsklinikum Hamburg-Eppendorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katja Weisel, MD
Role: PRINCIPAL_INVESTIGATOR
University Medical Center of Hamburg-Eppendorf
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Hamburg Eppendorf
Hamburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PV7313
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.